Managing many patients with a urethral stricture: a cost-benefit analysis of treatment options

被引:0
|
作者
Ogbonna, BC [1 ]
机构
[1] Jos Univ Teaching Hosp, Dept Surg, Urol Unit, Jos, Nigeria
来源
BRITISH JOURNAL OF UROLOGY | 1998年 / 81卷 / 05期
关键词
urethral strictures; urethrotomy; developing country; management;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To report a management method in a community where there are many patients with urethral stricture and where the short-term goal of providing some treatment to most may override the sometimes conflicting long-term aim of minimizing recurrence rates. Patients and methods Over a 3-year period, using optical urethrotomy in 76 patients followed by intermittent self-dilatation (ISD) in 29, urethroplasty in 28 and dilatation in three, 92 of 134 patients with a urethral stricture were treated and the outcome compared. Results The overall recurrence rate was 22%; a combination of urethrotomy plus ISD had a recurrence rate of 17% and gave a mean duration of follow-up without recurrence similar to that after urethroplasty, ISD significantly increased both the time before recurrence and the duration of follow-up without recurrence after urethrotomy. In addition to providing lasting treatment to many patients, urethrotomy was also 10 times cheaper, 10 times faster to perform and offered the surgeon better protection from infection with human immunodeficiency virus than did urethroplasty. Conclusion Because wrongly selecting urethrotomy (resulting in a failed procedure) wastes valuable operating time and resources, the pre-operative recognition of strictures unsuitable for urethrotomy and their treatment by urethroplasty is important for overall efficiency.
引用
收藏
页码:741 / 744
页数:4
相关论文
共 50 条
  • [41] Environmental Cost-Benefit Analysis
    Atkinson, Giles
    Mourato, Susana
    ANNUAL REVIEW OF ENVIRONMENT AND RESOURCES, 2008, 33 : 317 - 344
  • [42] On justifying cost-benefit analysis
    Kornhauser, LA
    JOURNAL OF LEGAL STUDIES, 2000, 29 (02): : 1037 - 1057
  • [43] Managing the insolvable limitations of cost-benefit analysis: results of an interview based study
    Niek Mouter
    Jan Anne Annema
    Bert van Wee
    Transportation, 2015, 42 : 277 - 302
  • [44] Managing the insolvable limitations of cost-benefit analysis: results of an interview based study
    Mouter, Niek
    Annema, Jan Anne
    van Wee, Bert
    TRANSPORTATION, 2015, 42 (02) : 277 - 302
  • [45] A Cost-Benefit Analysis of a Family Systems Intervention for Managing Pediatric Chronic Illness
    Distelberg, Brian J.
    Emerson, Natacha D.
    Gavaza, Paul
    Tapanes, Daniel
    Brown, Whitney N.
    Shah, Huma
    Williams-Reade, Jacqueline
    Montgomery, Susanne
    JOURNAL OF MARITAL AND FAMILY THERAPY, 2016, 42 (03) : 371 - 382
  • [46] COST-BENEFIT IN TREATMENT OF MILD HYPERTENSION
    HARVALD, B
    CHRISTIANSEN, T
    PEDERSEN, KM
    RASMUSSEN, K
    STRATE, M
    THYGESEN, K
    ACTA MEDICA SCANDINAVICA, 1984, : 81 - 87
  • [47] Cost-benefit considerations in the treatment of schizophrenia
    Kissling, W
    Seemann, U
    NORDIC JOURNAL OF PSYCHIATRY, 2000, 54 : 22 - 23
  • [48] COST-BENEFIT AND COST-EFFECTIVENESS ANALYSIS
    SCHOR, IM
    NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (07): : 432 - 432
  • [49] Cost-Benefit Analysis of Risperidone and Clozapine in the Treatment of Schizophrenia in Israel
    Gary Ginsberg
    Segev Shani
    Boaz Lev
    PharmacoEconomics, 1998, 13 : 231 - 241
  • [50] Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis
    Ginsberg, GM
    Lev, B
    PHARMACOECONOMICS, 1997, 12 (05) : 578 - 584